Adaptimmune and GSK announced their strategic collaboration and license agreement in June 2014 (https://bit.ly/2z1qMTn) for up to five programs including the first program, NY-ESO. The terms of the agreement were expanded in February 2016 (https://bit.ly/2IJ59qI) to accelerate development of NY-ESO SPEAR T-cell therapy toward registration trials in synovial sarcoma, to explore development in myxoid/round cell liposarcoma (MRCLS), and to enable combination studies. In September 2017, GSK exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program (https://bit.ly/2wMJKda).
In July 2018, we announced the transition of the NY-ESO program to GSK. As a result of the transition, GSK has assumed full responsibility for future research, development, and potential commercialization of this pioneering therapy, and Adaptimmune has received $27.5 million (£21.2 million) from GSK.
Following the transition of the NY-ESO program, GSK has the right to nominate its third and fourth targets. GSK already nominated PRAME as its second target in January 2017 (https://bit.ly/2jCixVu). GSK is not able to nominate targets on which Adaptimmune is already working, including ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP) SPEAR T-cells as well as its active preclinical pipeline. Adaptimmune will take these three additional targets when nominated, including PRAME, through preclinical testing to an IND‑ready state, at which point GSK will be responsible for IND filing. Adaptimmune will not be responsible for any clinical work on these additional programs.
"This is a turning point for Adaptimmune. We are extremely proud of the partnership with GSK and the pioneering work we have led over the years with NY-ESO SPEAR T-cells, as the foundation of our targeted TCR therapies, showing responses in two solid tumors and treating more than 80 patients in six different indications. With the NY‑ESO program transitioned, Adaptimmune can focus its clinical, regulatory and manufacturing resources on the development of our wholly owned therapies ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP). We will continue the preclinical work with GSK on its next target, PRAME."
James Noble, CEO, Adaptimmune